Rani Therapeutics Holdings, Inc. (RANI)
After hours:
| Previous close | 6.56 |
| Open | 6.48 |
| Bid | 6.68 x 200 |
| Ask | 6.69 x 100 |
| Day's range | 6.35 - 6.69 |
| 52-week range | 1.82 - 8.75 |
| Volume | |
| Avg. volume | 129,363 |
| Market cap | 345.757M |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.33 |
| Earnings date | 20 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.86 |
Insider MonkeyRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript March 20, 2024 Rani Therapeutics Holdings, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.33. RANI isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Kiki Patel: Operator: Welcome to […]
- Thomson Reuters StreetEvents
Q4 2023 Rani Therapeutics Holdings Inc Earnings Call
Q4 2023 Rani Therapeutics Holdings Inc Earnings Call
GlobeNewswireRani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist - - Cash runway extended into 2025 - - Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT - SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on
